Search results for "Highlights"
DPP-4 inhibitors associated with risk of cholecystitis, meta-analysis finds
Patients with type 2 diabetes who were randomized to receive dipeptidyl peptidase-4 (DPP-4) inhibitors had higher rates of gallbladder disease than those who got placebo or nonincretin drugs, but no difference in risk of cholelithiasis or biliary diseases.
https://diabetes.acponline.org/archives/2022/07/08/1.htm
8 Jul 2022
Report and study highlight risk of heart failure in patients with diabetes
The American Diabetes Association made recommendations on diagnosing and treating heart failure in patients with diabetes, and a study found increased risk of progression to clinical heart failure in those with an HbA1c level of 7% or above.
https://diabetes.acponline.org/archives/2022/06/10/1.htm
10 Jun 2022
Whole, plant-based diet most effective for type 2 diabetes remission, ACLM says
Diet as a primary intervention can achieve remission for many with type 2 diabetes and should focus on plant-based foods with minimal consumption of meat and other animal products, according to a statement from the American College of Lifestyle Medicine (ACLM).
https://diabetes.acponline.org/archives/2022/06/10/3.htm
10 Jun 2022
SGLT-2 inhibitors associated with reduced heart failure events versus metformin
A retrospective study of patients who took sodium-glucose cotransporter-2 (SGLT-2) inhibitors or metformin as first-line therapy for type 2 diabetes found similar risk for myocardial infarction and stroke with the two drug classes but a difference in hospitalizations for heart failure.
https://diabetes.acponline.org/archives/2022/06/10/2.htm
10 Jun 2022
Spotlight on efficacy of SGLT-2 inhibitors and GLP-1 receptor agonists
One recent study compared sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists to each other, a meta-analysis tried to quantify their benefits compared to placebo, and a third study looked at their effects relative to insulin.
https://diabetes.acponline.org/archives/2022/05/13/5.htm
13 May 2022
Cystatin C levels associated with risk of sight-threatening diabetic retinopathy
The biomarker may be useful for predicting this condition, especially in areas that don't have access to retinal imaging, according to an analysis of ophthalmology patients in the United Kingdom and India.
https://diabetes.acponline.org/archives/2022/05/13/3.htm
13 May 2022
HbA1c, CGM data significantly differed in patients with kidney disease
Patients with diabetes and chronic kidney disease often had discordance between their HbA1c levels and continuous glucose monitoring (CGM) data, with the HbA1c being significantly higher on average than the CGM-calculated glucose, a French study found.
https://diabetes.acponline.org/archives/2022/05/13/2.htm
13 May 2022
Moderating carbohydrates associated with lower mortality rates in type 2 diabetes
An observational study based on U.S. data compared hazard ratios for death based on overall, unhealthy, and healthy low-carb diet scores according to percentage of energy obtained from total and subtypes of carbohydrate, protein, and fat.
https://diabetes.acponline.org/archives/2022/05/13/1.htm
13 May 2022
GLP-1 receptor agonists linked to increased risk of gallbladder, biliary diseases
A systematic review and meta-analysis of 76 randomized trials found that use of glucagon-like peptide-1 (GLP-1) receptor agonists was associated with increased risk of gallbladder or biliary diseases, especially when used at higher doses, for longer durations, and for weight loss.
https://diabetes.acponline.org/archives/2022/04/08/2.htm
8 Apr 2022
Unrecognized risk factors for severe hypoglycemia outlined in insulin-treated type 2 diabetes
An industry-funded case-control study of data from a U.S. administrative claims database found that pregnancy, alcohol misuse, short or rapid-acting insulin, and smoking, among other conditions and medications, were independently associated with increased risk.
https://diabetes.acponline.org/archives/2022/04/08/3.htm
8 Apr 2022